Buying PIRS (Pieris Pharmaceuticals) after their AZN (Astrazeneca) partnership for an $1,800 gain.

PIRS recently partnered with AZN –  a deal that resulted in $45 million in up-front cash, with additional financing for development and commercialization incentives. After the news, institutional scaling began, and a clean step-up pattern ensued to confirm this as a low risk swing play.